Background: Antimicrobial resistance (AMR) threatens the efficacy of antimicrobials in equine patients. Extended-spectrum b-lactamases (ESBL) confer resistance to third generation cephalosporins (3GC) and are often associated with multi-drug resistance (MDR, resistance to ≥3 antimicrobial classes) in Escherichia coli.
Objectives: To determine the prevalence, patterns and risk factors of ESBL-producing faecal E. coli carried by horses at five UK equine hospitals.
Study design: Prospective multicentre cross-sectional study.
Methods: Each hospital was sampled for 3 weeks: faecal samples and data were collected daily from inpatients. Samples were inoculated on to Harlequin agar+cefotaxime (3GC), incubated overnight at 37°C and were confirmed as ESBL-producers by double-disc diffusion test, with susceptibility performed against clinically relevant antimicrobials. E. coli isolates were screened by PCR assay for relevant ESBL genes.
Results: 753 faecal samples were collected from 217 horses. ESBLproducing E. coli were detected in 46.1% samples (n = 347) (range 22.6-88.2% between hospitals). AMR was detected to ceftiofur (93.7% n = 325), gentamicin (91.4%, n = 317), trimethoprim/sulfamethoxazole (85.9%, n = 298), doxycycline (85.0%, n = 295) and enrofloxacin (27.1%, n = 94), with MDR detected in the majority (94.2%) of samples with ESBL-producing E. coli. The blaCTX-M gene responsible for ESBLphenotype was detected in 91.4% of samples. Ongoing analysis aims to identify other genes responsible for the resistance phenotypes.
Main limitations:
The high prevalence of multidrug resistant bacteria cultured from these horses represents faecal carriage rather than clinical infections and their role in the spread of hospital-acquired infections needs further investigation.
Conclusions: This study demonstrated a high prevalence of carriage of ESBL-producing E. coli from faeces of hospitalised horses with a high proportion of MDR isolates; however, there was wide variation between hospitals. Strategies aimed at identifying and limiting risk factors associated with carriage are important to reduce AMR in hospitalised patients. Methods: Clinical records of horses treated with LAIOMEP (BOVA UK) at Rainbow Equine Hospital were reviewed. Horses with EGGD or ESGD received IM injections of LAIOMEP on Days 1 and 7 and had repeat endoscopy performed on Days 11-19. If lesions had not resolved, then one or two further injections were administered at 7-day intervals and endoscopy was repeated around 7 days thereafter. Recommendations for diet and management were standardised. Clinical signs were assessed by owners. Endoscopy images were anonymised and reviewed by DR who was blinded to the identity of the patient and the stage of treatment.
Results: 31 cases of EGGD and 29 cases of ESGD were identified in 36 horses. Clinical signs were resolved or improved in 48% and 87% of EGGD cases and 52% and 90% of ESGD cases at 2 weeks. Clinical signs resolved in a further 13% and 3% of EGGD and ESGD cases by 4 weeks. Gastric lesions resolved or improved in endoscopic appearance in 58% and 86% of EGGD cases and 86% and 96% of ESGD cases at 2 weeks. By 4 weeks lesions had resolved in 81% of EGGD cases and 100% of ESGD cases. Six localised injection site reactions were observed in four horses from a total of 116 injections (5%); they were not associated with pain, did not require treatment and did not result in long-term complications.
Main limitations: Small numbers and absence of a control population.
Conclusions: LAIOMEP is a safe and effective treatment for EGGD and ESGD and resulted in more rapid healing in the study population than has been reported previously.
Ethical animal research: Informed client consent was obtained from all owners to use an unlicensed product and to publish clinical data. The study was approved by The University of Nottingham Animal Welfare and Ethical Review Body. Sources of funding: None. Competing interests D. Rendle has received payment for consultancy services provided to BOVA UK but received no payment for involvement in this study. Objectives: To describe the surgical outcomes and owner satisfaction following 980 nm laser excision of sarcoids.
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